throbber

`
` HIGHLIGHTS OF PRESCRIBING INFORMATION
`
`
`
` These highlights do not include all the information needed to use
` IMBRUVICA safely and effectively. See full prescribing information for
`
`
`
` IMBRUVICA.
`IMBRUVICA® (ibrutinib) capsules, for oral use
`
`
`
`
`
`
`
`IMBRUVICA® (ibrutinib) tablets, for oral use
`
`Initial U.S. Approval: 2013
`
`----------------------------RECENT MAJOR CHANGES-------------------------­
`
`
`
`Dosage and Administration (2.2, 2.4)
`01/2019
`
`
`
`Warnings and Precautions (5.1, 5.2, 5.3, 5.4, 5.5, 5.6)
`07/2019
`
`
`
`----------------------------INDICATIONS AND USAGE--------------------------­
`
`
`IMBRUVICA is a kinase inhibitor indicated for the treatment of adult patients
`
`with:
`
`
`
`• Mantle cell lymphoma (MCL) who have received at least one prior
`
`therapy (1.1).
`
`
`
`Accelerated approval was granted for this indication based on overall
`
`
`response rate. Continued approval for this indication may be contingent
`
`
`
`
`upon verification and description of clinical benefit in a confirmatory
`
`trial.
`
`
`• Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma
`
`(SLL) (1.2).
`
`
`• Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma
`
`
`
`(SLL) with 17p deletion (1.3).
`
`
`• Waldenström’s macroglobulinemia (WM) (1.4).
`
`
`
`• Marginal zone lymphoma (MZL) who require systemic therapy and have
`
`received at least one prior anti-CD20-based therapy (1.5).
`
`
`
`Accelerated approval was granted for this indication based on overall
`
`
`
`
`response rate. Continued approval for this indication may be contingent
`
`
`
`
`
`upon verification and description of clinical benefit in a confirmatory trial.
`
`
`
`
`
`• Chronic graft versus host disease (cGVHD) after failure of one or more
`
`lines of systemic therapy (1.6).
`
`-----------------------DOSAGE AND ADMINISTRATION----------------------­
`
`
`
`
`
`• MCL and MZL: 560 mg taken orally once daily (2.2).
`
`
`
`• CLL/SLL, WM, and cGVHD: 420 mg taken orally once daily (2.2).
`
`
`
`
`
`Dose should be taken orally with a glass of water. Do not open, break, or
`
`
`
`chew the capsules. Do not cut, crush, or chew the tablets (2.1).
`
`
`----------------------DOSAGE FORMS AND STRENGTHS--------------------­
`
`
`
`Capsules: 70 mg and 140 mg (3)
`
`
`
`
`Tablets: 140 mg, 280 mg, 420 mg, and 560 mg (3)
`
`
`
`
`
`
`
`
`
`
`------------------------------CONTRAINDICATIONS-----------------------------­
`None (4)
`
`
`------------------------WARNINGS AND PRECAUTIONS----------------------­
`
`• Hemorrhage: Monitor for bleeding and manage (5.1).
`
`
`• Infections: Monitor patients for fever and infections, evaluate promptly,
`
`
`
`
`
`
`and treat (5.2).
`
`
`• Cytopenias: Check complete blood counts monthly (5.3).
`
`
`• Cardiac arrhythmias: Monitor for symptoms of arrhythmias and manage
`
`
`
`
`(5.4).
`
`• Hypertension: Monitor blood pressure and treat (5.5).
`
`
`
`
`• Second Primary Malignancies: Other malignancies have occurred in
`
`
`
`patients, including skin cancers, and other carcinomas (5.6).
`
`• Tumor Lysis Syndrome (TLS): Assess baseline risk and take precautions.
`
`
`
`
`Monitor and treat for TLS (5.7).
`
`• Embryo-Fetal Toxicity: Can cause fetal harm. Advise women of the
`
`potential risk to a fetus and to avoid pregnancy while taking the drug and
`
`
`
`
`
`for 1 month after cessation of therapy. Advise men to avoid fathering a
`
`child during the same time period (5.8, 8.3).
`
`
`
`
`
`
`
`
`------------------------------ADVERSE REACTIONS------------------------------­
`The most common adverse reactions (≥20%) in patients with B-cell
`
`
`malignancies (MCL, CLL/SLL, WM and MZL) were thrombocytopenia,
`
`
`
`
`diarrhea, anemia, neutropenia, musculoskeletal pain, rash, bruising, nausea,
`
`
`
`
`fatigue, hemorrhage, and pyrexia (6).
`
`
`The most common adverse reactions (≥20%) in patients with cGVHD were
`
`
`
`fatigue, bruising, diarrhea, thrombocytopenia, muscle spasms, stomatitis,
`nausea, hemorrhage, anemia, and pneumonia (6).
`
`
`
`To report SUSPECTED ADVERSE REACTIONS, contact
`
`
`
`Pharmacyclics at 1-877-877-3536 or FDA at 1-800-FDA-1088 or
`
`
`
`
`www.fda.gov/medwatch.
`
`
`-------------------------------DRUG INTERACTIONS-----------------------------­
`
`• CYP3A Inhibitors: Modify IMBRUVICA dose as described (2.4, 7.1).
`
`
`
`
`
`
`
`• CYP3A Inducers: Avoid coadministration with strong CYP3A inducers
`
`
`
`
`
`(7.2).
`
`
`
`-----------------------USE IN SPECIFIC POPULATIONS-----------------------­
`Hepatic Impairment (based on Child-Pugh criteria): Avoid use of
`
`
`
`IMBRUVICA in patients with severe baseline hepatic impairment. In patients
`
`with mild or moderate impairment, reduce IMBRUVICA dose (2.5, 8.6).
`
`
`
`See 17 for PATIENT COUNSELING INFORMATION and FDA
`
`
`approved patient labeling.
`
`
`
`
`Revised: 07/2019
`
`
`
`
`
`
`
`FULL PRESCRIBING INFORMATION: CONTENTS*
`
`
`1
`INDICATIONS AND USAGE
`
`
`1.1 Mantle Cell Lymphoma
`
`
`
`Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
`1.2
`
`
`1.3
`Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
`
`
`
`
`with 17p deletion
`
`
`
`1.4 Waldenström’s Macroglobulinemia
`
`1.5 Marginal Zone Lymphoma
`
`
`1.6
`Chronic Graft versus Host Disease
`
`
`
`2 DOSAGE AND ADMINISTRATION
`
`
`2.1 Dosing Guidelines
`
`
`2.2
`Recommended Dosage
`
`
`
`2.3 Dose Modifications for Adverse Reactions
`
`
`2.4 Dose Modifications for Use with CYP3A Inhibitors
`
`
`
`2.5 Dose Modifications for Use in Hepatic Impairment
`
`
`2.6 Missed Dose
`
`
`3 DOSAGE FORMS AND STRENGTHS
`
`
`4 CONTRAINDICATIONS
`
`
`5 WARNINGS AND PRECAUTIONS
`
`
`5.1 Hemorrhage
`
`
`5.2
`Infections
`
`
`5.3
`Cytopenias
`5.4
`Cardiac Arrhythmias
`
`
`
`
`5.5 Hypertension
`
`
`5.6
`Second Primary Malignancies
`
`
`5.7
`Tumor Lysis Syndrome
`
`
`
`5.8
`Embryo-Fetal Toxicity
`
`
`6 ADVERSE REACTIONS
`
`
`6.1
`Clinical Trials Experience
`
`
`7
`
`
`
`Postmarketing Experience
`6.2
`
`DRUG INTERACTIONS
`
`
`
`Effect of CYP3A Inhibitors on Ibrutinib
`7.1
`
`
`
`
`Effect of CYP3A Inducers on Ibrutinib
`7.2
`
`
`
`
`8 USE IN SPECIFIC POPULATIONS
`
`
`8.1
`Pregnancy
`
`
`8.2
`Lactation
`
`
`8.3
`Females and Males of Reproductive Potential
`
`
`
`8.4
`Pediatric Use
`
`
`8.5 Geriatric Use
`
`
`8.6 Hepatic Impairment
`
`
`8.7
`Plasmapheresis
`
`
`10 OVERDOSAGE
`
`
`11 DESCRIPTION
`
`
`12 CLINICAL PHARMACOLOGY
`
`
`12.1 Mechanism of Action
`
`
`12.2 Pharmacodynamics
`
`
`12.3 Pharmacokinetics
`
`
`13 NONCLINICAL TOXICOLOGY
`
`
`13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
`
`
`
`14 CLINICAL STUDIES
`
`
`14.1 Mantle Cell Lymphoma
`
`
`
`14.2 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
`
`
`
`14.3 Waldenström’s Macroglobulinemia
`
`14.4 Marginal Zone Lymphoma
`
`
`14.5 Chronic Graft versus Host Disease
`
`
`
`16 HOW SUPPLIED/STORAGE AND HANDLING
`
`
`
`17 PATIENT COUNSELING INFORMATION
`* Sections or subsections omitted from the full prescribing information are
`
`
`
`not listed.
`
`
`Reference ID: 4462109
`
`
`
` 1
`
`

`

`
`
`
`
`
`
`
` FULL PRESCRIBING INFORMATION
`
`
` 1
` INDICATIONS AND USAGE
` 1.1 Mantle Cell Lymphoma
`
`
` IMBRUVICA is indicated for the treatment of adult patients with mantle cell lymphoma (MCL)
`
` who have received at least one prior therapy.
`Accelerated approval was granted for this indication based on overall response rate. Continued
`approval for this indication may be contingent upon verification and description of clinical
`
`benefit in a confirmatory trial [see Clinical Studies (14.1)].
`
`
`Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
`1.2
`
`
`
`IMBRUVICA is indicated for the treatment of adult patients with chronic lymphocytic leukemia
`
`(CLL)/small lymphocytic lymphoma (SLL).
`
`Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma with 17p deletion
`1.3
`
`
`
`IMBRUVICA is indicated for the treatment of adult patients with chronic lymphocytic leukemia
`
`(CLL)/small lymphocytic lymphoma (SLL) with 17p deletion.
`
`
`1.4 Waldenström’s Macroglobulinemia
`
`
`IMBRUVICA is indicated for the treatment of adult patients with Waldenström’s
`
`macroglobulinemia (WM).
`
`1.5 Marginal Zone Lymphoma
`
`
`IMBRUVICA is indicated for the treatment of adult patients with marginal zone lymphoma
`
`(MZL) who require systemic therapy and have received at least one prior anti-CD20-based
`
`therapy.
`
`Accelerated approval was granted for this indication based on overall response rate [see Clinical
`
`
`Studies (14.4)]. Continued approval for this indication may be contingent upon verification and
`
`description of clinical benefit in a confirmatory trial.
`
`1.6
`Chronic Graft versus Host Disease
`
`
`IMBRUVICA is indicated for the treatment of adult patients with chronic graft-versus-host
`
`disease (cGVHD) after failure of one or more lines of systemic therapy.
`
`2
`DOSAGE AND ADMINISTRATION
`
`
`2.1
`Dosing Guidelines
`
`
`Administer IMBRUVICA orally once daily at approximately the same time each day. The dose
`
`
`
`should be taken orally with a glass of water. Do not open, break, or chew the capsules. Do not
`
`
`cut, crush, or chew the tablets.
`
`
`
`Reference ID: 4462109
`
`
`2
`
`

`

`
`
`
`
`
`
`
` Recommended Dosage
` 2.2
`
`
` Mantle Cell Lymphoma and Marginal Zone Lymphoma
`
`
`
` The recommended dose of IMBRUVICA for MCL and MZL is 560 mg orally once daily until
` disease progression or unacceptable toxicity.
`
` Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Waldenström’s
`
` Macroglobulinemia
` The recommended dose of IMBRUVICA for CLL/SLL and WM as a single agent, in
`
`
`combination with rituximab for WM, or in combination with bendamustine and rituximab or
`with obinutuzumab for CLL/SLL is 420 mg orally once daily until disease progression or
`
`
`unacceptable toxicity.
`
`When administering IMBRUVICA in combination with rituximab or obinutuzumab, consider
`
`
`
`administering IMBRUVICA prior to rituximab or obinutuzumab when given on the same day.
`
`
`
`Chronic Graft versus Host Disease
`
`The recommended dose of IMBRUVICA for cGVHD is 420 mg orally once daily until cGVHD
`
`
`
`
`progression, recurrence of an underlying malignancy, or unacceptable toxicity. When a patient
`
`no longer requires therapy for the treatment of cGVHD, IMBRUVICA should be discontinued
`
`considering the medical assessment of the individual patient.
`
`2.3
`Dose Modifications for Adverse Reactions
`
`
`Interrupt IMBRUVICA therapy for any Grade 3 or greater non-hematological toxicities, Grade 3
`
`
`
`or greater neutropenia with infection or fever, or Grade 4 hematological toxicities. Once the
`
`symptoms of the toxicity have resolved to Grade 1 or baseline (recovery), IMBRUVICA therapy
`
`
`
`may be reinitiated at the starting dose. If the toxicity reoccurs, reduce dose by 140 mg per day. A
`
`
`
`
`second reduction of dose by 140 mg may be considered as needed. If these toxicities persist or
`
`
`
`
`recur following two dose reductions, discontinue IMBRUVICA.
`
`
`
`Recommended dose modifications are described below:
`
`
`
`
` Toxicity Occurrence
`First
`
`
` Second
`
` Third
` Fourth
`
`
`Reference ID: 4462109
`
`
`
`
`
`
` Dose Modification for MCL and
` MZL After Recovery
`
` Starting Dose = 560 mg
`Restart at 560 mg daily
`
`
`
`
` Restart at 420 mg daily
`
`
`
` Restart at 280 mg daily
`
`
` Discontinue IMBRUVICA
`
`
`
`
`
`
`
` Dose Modification for CLL/SLL,
`
` WM, and cGVHD After Recovery
`
` Starting Dose = 420 mg
`
`Restart at 420 mg daily
`
`
`
`
` Restart at 280 mg daily
`
`
`
` Restart at 140 mg daily
`
`
` Discontinue IMBRUVICA
`
`
`
`3
`
`

`

`
` Dose Modifications for Use with CYP3A Inhibitors
` 2.4
`
`
`
`
` Recommended dose modifications are described below [see Drug Interactions (7.1)]:
`
`
`
`
`
`
` Patient Population Coadministered Drug
` B-Cell Malignancies • Moderate CYP3A inhibitor
`
`
`
`
`
`• Voriconazole 200 mg twice daily
`
`
`• Posaconazole suspension 100 mg
`
`
`once daily, 100 mg twice daily, or
`
`200 mg twice daily
`
`
`• Posaconazole suspension 200 mg
`
`
`three times daily or 400 mg twice
`
`daily
`
`• Posaconazole IV injection 300 mg
`
`
`once daily
`
`• Posaconazole delayed-release tablets
`
`300 mg once daily
`
`
`• Other strong CYP3A inhibitors
`
`
`
`
`Chronic Graft versus
`
`Host Disease
`
`
`• Moderate CYP3A inhibitor
`
`
`
`
`
`• Voriconazole 200 mg twice daily
`
`
`• Posaconazole suspension 100 mg
`
`once daily, 100 mg twice daily, or
`
`200 mg twice daily
`
`
` • Posaconazole suspension 200 mg
`
`
` three times daily or 400 mg twice
`
` daily
` • Posaconazole IV injection 300 mg
`
`
` once daily
` • Posaconazole delayed-release tablets
`
` 300 mg once daily
`
`• Other strong CYP3A inhibitors
`
`
`
`
`
`
`
`
` Recommended IMBRUVICA Dose
`
` 280 mg once daily
`Modify dose as recommended [see
`
` Dosage and Administration (2.3)].
`
`140 mg once daily
`
`
`Modify dose as recommended [see
`
`Dosage and Administration (2.3)].
`
`70 mg once daily
`
`
`Interrupt dose as recommended [see
`
`Dosage and Administration (2.3)].
`
`Avoid concomitant use.
`
`If these inhibitors will be used short-
`term (such as anti-infectives for seven
`
`days or less), interrupt IMBRUVICA.
`
`
`420 mg once daily
`
`Modify dose as recommended [see
`
`
`Dosage and Administration (2.3)].
`
`280 mg once daily
`Modify dose as recommended [see
`
`Dosage and Administration (2.3)].
`
` 140 mg once daily
`
`
` Interrupt dose as recommended [see
` Dosage and Administration (2.3)].
`
`
`Avoid concomitant use.
`
`If these inhibitors will be used short-
`term (such as anti-infectives for seven
`
`days or less), interrupt IMBRUVICA.
`
`
`
` After discontinuation of a CYP3A inhibitor, resume previous dose of IMBRUVICA [see Dosage
` and Administration (2.2) and Drug Interactions (7.1)].
`
`
`
`
`Reference ID: 4462109
`
`
`4
`
`

`

`
` Dose Modifications for Use in Hepatic Impairment
` 2.5
`
`
`The recommended dose is 140 mg daily for patients with mild hepatic impairment (Child-Pugh
`class A).
`
`The recommended dose is 70 mg daily for patients with moderate hepatic impairment (Child-
`Pugh class B).
`
`
`Avoid the use of IMBRUVICA in patients with severe hepatic impairment (Child-Pugh class C)
`
`
`[see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)].
`
`
`2.6 Missed Dose
`
`
`If a dose of IMBRUVICA is not taken at the scheduled time, it can be taken as soon as possible
`
`
`on the same day with a return to the normal schedule the following day. Extra doses of
`
`
`IMBRUVICA should not be taken to make up for the missed dose.
`
`
`DOSAGE FORMS AND STRENGTHS
`3
`
`
`Capsules:
`
`
`Each 70 mg capsule is a yellow, opaque capsule marked with “ibr 70 mg” in black ink.
`
`
`
`
`Each 140 mg capsule is a white, opaque capsule marked with “ibr 140 mg” in black ink.
`
`
`
`Tablets:
`
`
`Each 140 mg tablet is a yellow green to green round tablet debossed with “ibr” on one side and
`
`
`“140” on the other side.
`
`
`Each 280 mg tablet is a purple oblong tablet debossed with “ibr” on one side and “280” on the
`
`
`other side.
`
`
`Each 420 mg tablet is a yellow green to green oblong tablet debossed with “ibr” on one side and
`
`
`“420” on the other side.
`
`
`Each 560 mg tablet is a yellow to orange oblong tablet debossed with “ibr” on one side and
`
`
`
`“560” on the other side.
`
`
`CONTRAINDICATIONS
`4
`
`
`None
`
`WARNINGS AND PRECAUTIONS
`5
`
`
`5.1 Hemorrhage
`
`
`Fatal bleeding events have occurred in patients treated with IMBRUVICA. Major hemorrhage
`
`(≥ Grade 3, serious, or any central nervous system events; e.g., intracranial hemorrhage
`
`
`
`
`
`[including subdural hematoma], gastrointestinal bleeding, hematuria, and post procedural
`
`hemorrhage) have occurred in 4% of patients, with fatalities occurring in 0.4% of 2,838 patients
`
`
`
`
`
`exposed to IMBRUVICA in 27 clinical trials. Bleeding events of any grade, including bruising
`
`
`
`and petechiae, occurred in 39% of patients treated with IMBRUVICA.
`
`
`
`
`5
`
`Reference ID: 4462109
`
`

`

`
`
`
` The mechanism for the bleeding events is not well understood.
` Use of either anticoagulant or antiplatelet agents concomitantly with IMBRUVICA increases the
`
`
`risk of major hemorrhage. In IMBRUVICA clinical trials, 3.1% of patients taking IMBRUVICA
`
`
`
`
`
`without antiplatelet or anticoagulant therapy experienced major hemorrhage. The addition of
`
`
`
`antiplatelet therapy with or without anticoagulant therapy increased this percentage to 4.4%, and
`
`
`
`
`
`
`the addition of anticoagulant therapy with or without antiplatelet therapy increased this
`
`
`
`percentage to 6.1%. Consider the risks and benefits of anticoagulant or antiplatelet therapy when
`
`
`co-administered with IMBRUVICA. Monitor for signs and symptoms of bleeding.
`
`
`Consider the benefit-risk of withholding IMBRUVICA for at least 3 to 7 days pre- and post-
`
`
`
`
`surgery depending upon the type of surgery and the risk of bleeding [see Clinical Studies (14)].
`
`
`
`5.2
`Infections
`
`
`Fatal and non-fatal infections (including bacterial, viral, or fungal) have occurred with
`IMBRUVICA therapy. Grade 3 or greater infections occurred in 24% of 1,124 patients exposed
`
`
`
`to IMBRUVICA in clinical trials [see Adverse Reactions (6.1, 6.2)]. Cases of progressive
`
`
`multifocal leukoencephalopathy (PML) and Pneumocystis jirovecii pneumonia (PJP) have
`
`
`
` occurred in patients treated with IMBRUVICA. Consider prophylaxis according to standard of
`
` care in patients who are at increased risk for opportunistic infections. Monitor and evaluate
`
` patients for fever and infections and treat appropriately.
`
`
` 5.3
` Cytopenias
`
` Treatment-emergent Grade 3 or 4 cytopenias including neutropenia (23%), thrombocytopenia
`
` (8%), and anemia (3%) based on laboratory measurements occurred in patients with B-cell
`
` malignancies treated with single agent IMBRUVICA.
`
`Monitor complete blood counts monthly.
`
`
`5.4
`Cardiac Arrhythmias
`
`
`Fatal and serious cardiac arrhythmias have occurred with IMBRUVICA therapy. Grade 3 or
`
`
`
`greater ventricular tachyarrhythmias occurred in 0.2% of patients, and Grade 3 or greater atrial
`
`
`
`
`fibrillation and atrial flutter occurred in 4% of 1,124 patients exposed to IMBRUVICA in
`
`
`clinical trials. These events have occurred particularly in patients with cardiac risk factors,
`
`
`hypertension, acute infections, and a previous history of cardiac arrhythmias. See Additional
`
`Important Adverse Reactions (6.1).
`
`
`
`Periodically monitor patients clinically for cardiac arrhythmias. Obtain an ECG for patients who
`
`develop arrhythmic symptoms (e.g., palpitations, lightheadedness, syncope, chest pain) or new
`
`
`onset dyspnea. Manage cardiac arrhythmias appropriately, and if it persists, consider the risks
`
`
`and benefits of IMBRUVICA treatment and follow dose modification guidelines [see Dosage
`
`and Administration (2.3)].
`
`
`5.5 Hypertension
`
`
`6
`
`Reference ID: 4462109
`
`

`

`
`
`
`
` Hypertension of any grade occurred in 12% of 1,124 patients treated with IMBRUVICA in
`clinical trials. Grade 3 or greater hypertension occurred in 5% of patients with a median time to
`
`
`
`onset of 5.9 months (range, 0.03 to 24 months).
`
`
`
`
`Monitor blood pressure in patients treated with IMBRUVICA and initiate or adjust anti-
`
`
`hypertensive medication throughout treatment with IMBRUVICA as appropriate.
`
`
`
`Second Primary Malignancies
`5.6
`
`
`Other malignancies (10%) including non-skin carcinomas (4%) have occurred in 1,124 patients
`
`
`
`
`treated with IMBRUVICA in clinical trials. The most frequent second primary malignancy was
`
`
`
`non-melanoma skin cancer (6%).
`
`Tumor Lysis Syndrome
`5.7
`
`
`Tumor lysis syndrome has been infrequently reported with IMBRUVICA therapy. Assess the
`
`
`baseline risk (e.g., high tumor burden) and take appropriate precautions. Monitor patients closely
`
`
`and treat as appropriate.
`
`
`Embryo-Fetal Toxicity
`5.8
`
`
`Based on findings in animals, IMBRUVICA can cause fetal harm when administered to a
`
`
`
`
`pregnant woman. Administration of ibrutinib to pregnant rats and rabbits during the period of
`
`organogenesis caused embryo-fetal toxicity including malformations at exposures that were
`
`2-20 times higher than those reported in patients with hematologic malignancies. Advise women
`
`
`to avoid becoming pregnant while taking IMBRUVICA and for 1 month after cessation of
`
`
`
`therapy. If this drug is used during pregnancy or if the patient becomes pregnant while taking
`
`this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific
`
`Populations (8.1)].
`
`ADVERSE REACTIONS
`6
`
`
`The following clinically significant adverse reactions are discussed in more detail in other
`
`
`sections of the labeling:
`
`• Hemorrhage [see Warnings and Precautions (5.1)]
`
`
`
`
`
`Infections [see Warnings and Precautions (5.2)]
`
`
`
`
`
`•
`• Cytopenias [see Warnings and Precautions (5.3)]
`
`
`
`
`
`• Cardiac Arrhythmias [see Warnings and Precautions (5.4)]
`
`
`
`
`• Hypertension [see Warnings and Precautions (5.5)]
`
`
`
`
`
`• Second Primary Malignancies [see Warnings and Precautions (5.6)]
`
`
`
`
`• Tumor Lysis Syndrome [see Warnings and Precautions (5.7)]
`
`
`
`
`
`Clinical Trials Experience
`6.1
`
`
`
`Reference ID: 4462109
`
`
`7
`
`

`

`
` Because clinical trials are conducted under widely variable conditions, adverse event rates
`
`
` observed in clinical trials of a drug cannot be directly compared with rates of clinical trials of
`
`
`
` another drug and may not reflect the rates observed in practice.
` Mantle Cell Lymphoma
`
`The data described below reflect exposure to IMBRUVICA in a clinical trial (Study 1104) that
`
`
`included 111 patients with previously treated MCL treated with 560 mg daily with a median
`
`
`
`treatment duration of 8.3 months.
`
`The most commonly occurring adverse reactions (≥ 20%) were thrombocytopenia, diarrhea,
`
`neutropenia, anemia, fatigue, musculoskeletal pain, peripheral edema, upper respiratory tract
`
`infection, nausea, bruising, dyspnea, constipation, rash, abdominal pain, vomiting and decreased
`appetite (see Tables 1 and 2).
`
`
`
`The most common Grade 3 or 4 non-hematological adverse reactions (≥ 5%) were pneumonia,
`abdominal pain, atrial fibrillation, diarrhea, fatigue, and skin infections.
`
`
`Fatal and serious cases of renal failure have occurred with IMBRUVICA therapy. Increases in
`
`
`
`creatinine 1.5 to 3 times the upper limit of normal occurred in 9% of patients.
`
`
`Adverse reactions from the MCL trial (N=111) using single agent IMBRUVICA 560 mg daily
`
`
`
`
`occurring at a rate of ≥ 10% are presented in Table 1.
`
`
`
`
`
`
` General disorders and
`
` administration site
`
`conditions
`
`
` Skin and subcutaneous
`
` tissue disorders
`
` Body System
` Adverse Reaction
`
`
` Gastrointestinal disorders Diarrhea
`
`
` Nausea
` Constipation
`
`
` Abdominal pain
`
` Vomiting
`
` Stomatitis
`
` Dyspepsia
`
` Infections and infestations Upper respiratory tract infection
`
`
`
` Urinary tract infection
`
` Pneumonia
`
`
`Skin infections
` Sinusitis
`
`
` Fatigue
` Peripheral edema
`
`
` Pyrexia
`
` Asthenia
`
` Bruising
`
` Rash
` Petechiae
`
` Musculoskeletal pain
`
` Muscle spasms
`
`Table 1: Non-Hematologic Adverse Reactions in ≥ 10% of Patients with MCL (N=111)
`
`
`
` All Grades
`
` Grade 3 or
`
` Higher (%)
`
`
` (%)
`
` 51
`
` 5
`
` 31
`
` 0
`
` 25
`
` 0
`
` 24
`
` 5
`
` 23
`
` 0
`
` 17
`
` 1
`
` 11
`
` 0
`
` 34
`
` 0
`
` 14
`
` 3
`
` 14
` 8†
`
`
`
`14
`5
`
` 13
`
` 1
`
` 41
`
` 5
`
` 35
`
` 3
`
` 18
`
` 1
`
` 14
`
` 3
`
` 30
`
` 0
`
` 25
`
` 3
`
` 11
`
` 0
`
` 37
`
` 1
`
` 14
`
` 0
`
`Musculoskeletal and
` connective tissue disorders
`
`
`
`
`
`Reference ID: 4462109
`
`
`8
`
`

`

`
`
`
`
` Body System
`
`
`
`
` Respiratory, thoracic and
`
` mediastinal disorders
`
`
`
`
` All Grades
`
` (%)
`
` 11
`
` 27
`
` 19
`
` 11
`
` 21
`
` 12
`
` 14
`
` 13
`
`
` Grade 3 or
`
` Higher (%)
`
`
` 0
` 5†
`
`
` 0
`
` 0
`
` 2
`
` 4
`
` 0
`
` 0
`
`
`
`
`
` Adverse Reaction
`
` Arthralgia
`
` Dyspnea
`
` Cough
` Epistaxis
`
` Metabolism and nutrition
`
` Decreased appetite
`
` disorders
`
` Dehydration
` Nervous system disorders Dizziness
`
`
`
` Headache
` † Includes one event with a fatal outcome.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` Table 2: Treatment-Emergent* Hematologic Laboratory Abnormalities
`
`
` in Patients with MCL (N=111)
`
`
`
`
`
`
` Percent of Patients (N=111)
`
`
`Grade 3 or 4 (%)
`All Grades (%)
`
`
`
`57
`17
`
`
`47
`29
`
`
`41
`9
`
`
`
`
`Platelets Decreased
`
`Neutrophils Decreased
`
`Hemoglobin Decreased
`
` * Based on laboratory measurements and adverse reactions
`
`
` Treatment-emergent Grade 4 thrombocytopenia (6%) and neutropenia (13%) occurred in patients.
`
`
` Ten patients (9%) discontinued treatment due to adverse reactions in the trial (N=111). The most
`
`
` frequent adverse reaction leading to treatment discontinuation was subdural hematoma (1.8%).
`
` Adverse reactions leading to dose reduction occurred in 14% of patients.
`
`
` Patients with MCL who develop lymphocytosis greater than 400,000/mcL have developed
`
` intracranial hemorrhage, lethargy, gait instability, and headache. However, some of these cases
`
`
`
` were in the setting of disease progression.
`
` Forty percent of patients had elevated uric acid levels on study including 13% with values above
`
`
` 10 mg/dL. Adverse reaction of hyperuricemia was reported for 15% of patients.
` Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
`
`
`The data described below reflect exposure in one single-arm, open-label clinical trial
`
`
`
`(Study 1102) and four randomized controlled clinical trials (RESONATE, RESONATE-2, and
`
`
`
`
`
`HELIOS, and iLLUMINATE) in patients with CLL/SLL (n=1,506 total and n=781 patients
`
`
`exposed to IMBRUVICA). Patients with creatinine clearance (CrCl) ≤ 30 mL/min, AST or ALT
`
`
`
`
`
`
`
`≥ 2.5 x ULN (upper limit of normal), or total bilirubin ≥ 1.5x ULN (unless of non-hepatic origin)
`
`were excluded from these trials. Study 1102 included 51 patients with previously treated
`
`
`CLL/SLL, RESONATE included 386 randomized patients with previously treated CLL or SLL
`
`who received single agent IMBRUVICA or ofatumumab, RESONATE-2 included
`
`267 randomized patients with treatment naïve-CLL or SLL who were 65 years or older and
`
`Reference ID: 4462109
`
`
`9
`
`

`

`
`
`
` received single agent IMBRUVICA or chlorambucil, HELIOS included 574 randomized patients
`
`
`
`
` with previously treated CLL or SLL who received IMBRUVICA in combination with
`bendamustine and rituximab or placebo in combination with bendamustine and rituximab, and
`iLLUMINATE included 228 randomized patients with treatment naïve CLL who were 65 years
`
`
`
`
`or older or with coexisting medical conditions and received IMBRUVICA in combination with
`
`
`obinutuzumab or chlorambucil in combination with obinutuzumab.
`
`The most commonly occurring adverse reactions in patients with CLL/SLL receiving
`
`
`IMBRUVICA (≥ 20%) were neutropenia, thrombocytopenia, anemia, diarrhea, rash,
`
`
`musculoskeletal pain, bruising, nausea, fatigue, pyrexia, hemorrhage, and cough.
`
`
`Four to 10 percent of patients with CLL/SLL receiving IMBRUVICA discontinued treatment
`
`
`
`due to adverse reactions. These included pneumonia, hemorrhage, atrial fibrillation, rash and
`neutropenia. Adverse reactions leading to dose reduction occurred in approximately 7% of
`
`
`
`patients.
`
`Study 1102
`
`Adverse reactions and laboratory abnormalities from the CLL/SLL trial (N=51) using single
`
`
`agent IMBRUVICA 420 mg daily in patients with previously treated CLL/SLL occurring at a
`
`
`
`rate of ≥ 10% with a median duration of treatment of 15.6 months are presented in Tables 3
`
`
`and 4.
`
`
`
`Table 3: Non-Hematologic Adverse Reactions in ≥ 10% of Patients with
`
`
`CLL/SLL (N=51) in Study 1102
`
`
`
`
`
` Body System
`
` Gastrointestinal disorders
`
`
`
`
`
` Infections and infestations
`
` General disorders and
`
`administration site
`
`conditions
`
`
`Reference ID: 4462109
`
`
`
`
`
`
`
`
`
` Adverse Reaction
`
` Diarrhea
`
` Constipation
`
` Nausea
`
` Stomatitis
`
` Vomiting
`
` Abdominal pain
`
` Dyspepsia
` Upper respiratory tract infection
`
` Sinusitis
`
` Skin infection
`
` Pneumonia
` Urinary tract infection
`
`Fatigue
`
`Pyrexia
`
`Peripheral edema
`
`Asthenia
`
`Chills
`
`
`All Grades
`
` (%)
`
` 59
`
` 22
`
` 20
`
` 20
`
` 18
`
` 14
`
` 12
`
`47
`
` 22
`
`16
`
` 12
`
`12
`33
`
`24
`
`22
`
`14
`
`12
`
`
`
` Grade 3 or
`
` Higher (%)
`
`
` 4
`
` 2
`
` 2
`
` 0
`
` 2
`
` 0
`
` 0
`
`2
`
`6
`
`6
`
`10
`
`2
`6
`
`2
`
`0
`
`6
`
`0
`
`
`
`10
`
`

`

`
`
` Body System
`
`
` Skin and subcutaneous
`
` tissue disorders
`
`
`Respiratory, thoracic and
`
`mediastinal disorders
`
`Musculoskeletal and
` connective tissue disorders
`
`
`
`
`Nervous system disorders
`
`
`
`
`
` Adverse Reaction
`Bruising
`
`Rash
`
`Petechiae
`
`
`Cough
`
`Oropharyngeal pain
`
`Dyspnea
`Musculoskeletal pain
`
`Arthralgia
`
`Muscle spasms
`
`
`Dizziness
`
`Headache
` Decreased appetite
`
` Metabolism and nutrition
`
` disorders
` Neoplasms benign,
`
`
` malignant, unspecified
`
` Vascular disorders
` Hypertension
` †One patient death due to histiocytic sarcoma.
`
`
`
`
`
`Second malignancies
`
`
`
`
`All Grades
`
` (%)
`51
`
`25
`
`16
`
`
`22
`
`14
`
`12
`25
`
`24
`
`18
`
`
`20
`
`18
`
` 16
`
`10
`
`
`
`
` 16
`
`
` Grade 3 or
`
` Higher (%)
`
`2
`
`0
`
`0
`
`
`0
`
`0
`
`0
`6
`
`0
`
`2
`
`
`0
`
`2
`
` 2
`
`2†
`
`
`
`
` 8
`
` Table 4: Treatment-Emergent* Hematologic Laboratory Abnormalities
`
`
`
`
` in Patients with CLL/SLL (N=51) in Study 1102
`
`
`
`
`
`
`
`
` Percent of Patients (N=51)
`
`
`Grade 3 or 4 (%)
`All Grades (%)
`
`
`
`
`69
`12
`Platelets Decreased
`
`
`
`53
`26
`Neutrophils Decreased
`
`
`
`43
`Hemoglobin Decreased
`0
`
` * Based on laboratory measurements per IWCLL criteria and adverse reactions.
`
` Treatment-emergent Grade 4 thrombocytopenia (8%) and neutropenia (12%) occurred in patients.
`
`
` RESONATE
`
`
`
` Adverse reactions and laboratory abnormalities described below in Tables 5 and 6 reflect
`
`exposure to IMBRUVICA with a median duration of 8.6 months and exposure to ofatumumab
`
`
` with a median of 5.3 months in RESONATE in patients with previously treated CLL/SLL.
`
`
`
` Table 5: Adverse Reactions Reported in ≥ 10% of Patients and at Least 2% Greater in the
`
`
`
` IMBRUVICA Treated Arm in Patients with CLL/SLL in RESONATE
`
`
`Body System
`
`Adverse Reaction
`
`Gastrointestinal disorders
`
`
` IMBRUVICA
`
`(N=195)
` Grade 3 or
`
` All Grades
`
`
`
`(%)
` Higher (%)
`
`
`
`
`
` Ofatumumab
`
`(N=191)
`
` Grade 3 or
`
` All Grades
`
`
` Higher (%)
`(%)
`
`
`
`
`
`11
`
`Reference ID: 4462109
`
`

`

`
`
`
` IMBRUVICA
`
`(N=195)
` Grade 3 or
`
` All Grades
`
`
`
`(%)
` Higher (%)
`
`
`
`48
`4
`
`
`26
`2
`
`
`17
`1
`
`
`15
`0
`
`
`14
`0
`
`
`
`
` Ofatumumab
`
`(N=191)
`
` Grade 3 or
`
` All Grades
`
`
` Higher (%)
`(%)
`
`
`
`18
`2
`
`
`18
`0
`
`
`1
`6
`
`
`9
`0
`
`
`6
`1
`
`
`
`
`Body System
`
`Adverse Reaction
`
`Diarrhea
`
`Nausea
`
`Stomatitis*
`
`Constipation
`
`Vomiting
`General disorders and
`
`
`administration site conditions
`
`
`Pyrexia
`
`Infections and infestations
`
`
` Upper respiratory tract
`
`infection
`
`Pneumonia*
`
`Sinusitis*
`
` Urinary tract infection
`
` Skin and subcutaneous tissue
`
`
`disorders
`
`Rash*
`
`Petechiae
`
`Bruising*
`Musculoskeletal and
`
`connective tissue disorders
`
`Musculoskeletal pain*
`
`Arthralgia
`
`Nervous system disorders
`
`Headache
`
`Dizziness
` Injury, poisoning and
`
`
`procedural complications
`
`
`
`
`3
`0
`11
`Contusion
`
`
`
`
`Eye disorders
`
`
`
`
`3
`0
`10
`Vision blurred
`
`
`
`
` Subjects with multiple events for a given adverse reaction (ADR) term are counted once only for each ADR term.
` The body system and individual ADR terms are sorted in descending frequency order in the IMBRUVICA arm.
`
`
`
`* Includes multiple ADR terms
`
`† Includes 3 events of pneumonia with fatal outcome in each arm, and 1 event of pyrexia and upper respiratory tract infection with
`
`
`
`
`
`
`
`
`
` a fatal outcome in the ofatumumab arm.
`
`
`
`
`
`24
`
`
`16
`
`
`15
`
`11
`
`10
`
`
`
`24
`
`14
`
`12
`
`
`
`28
`
`17
`
`
`14
`
`11
`
`
`
`2
`
`
`1
`
`
`12†
`
`1
`
`4
`
`
`
`3
`
`0
`
`0
`
`
`
`2
`
`1
`
`
`1
`
`0
`
`
`
`15
`
`
`11
`
`
`13
`
`6
`
`5
`
`
`
`13
`
`1
`
`1
`
`
`
`18
`
`7
`
`
`6
`
`5
`
`
`
`2†
`
`
`2†
`
`
`10†
`
`0
`
`1
`
`
`
`0
`
`0
`
`0
`
`
`
`1
`
`0
`
`
`0
`
`0
`
`
`
`0
`
`
`0
`
`
`
`Reference ID: 4462109
`
`
`12
`
`

`

`
`
`
`
` Table 6: Treatment-Emergent Hematologic Laboratory Abnormalities in Patients with
`
`
` CLL/SLL in RESONATE
`
`
`
`
`
`
`
`
`Ofatumumab
`IMBRUVICA
`(N=191)
`(N=195)
`
`
`
` Grade 3 or 4
`
` All Grades
`
` All Grades
` Grade 3 or 4
`
`(%)
`(%)
`(%)
`(%)
`
`
`
`
`
` Neutrophils Decreased
`
`
` 57
` 26
`
`
` 51
` 23
`
` Platelets Decreased
`
` 45
`
` 10
`
` 52
`
` 5
` Hemoglobin Decreased
`
` 21
`
` 36
`
` 0
`
`
` 0
` Treatment-emergent Grade 4 thrombocytopenia (2% in the IMBRUVICA arm vs 3% in the ofatumumab arm) and neutropenia
`
`
`
`
`
` (8% in the IMBRUVICA arm vs 8% in the ofatumumab arm) occurred in patients.
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket